Press release
Exploring the Advancements in Familial Mediterranean Fever Clinical Trials: Anticipating the Arrival of 3+ Innovative Therapies into the Landscape, Insights by DelveInsight
(Albany, USA) DelveInsight's report titled "Familial Mediterranean Fever Pipeline Insight" offers extensive information on more than 3+ companies and over 3+ pipeline drugs in the field of Familial Mediterranean Fever research. The report encompasses detailed profiles of the pipeline drugs for Familial Mediterranean Fever, including information on clinical trials and nonclinical stage products.For the Familial Mediterranean Fever emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, and route of administration, molecule type, and mechanism of action (MOA). The research on the Familial Mediterranean Fever pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies.
To explore more information on the latest breakthroughs in the Familial Mediterranean Fever Pipeline treatment landscape of the report, click here @ Familial Mediterranean Fever Pipeline Outlook- https://www.delveinsight.com/report-store/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Familial Mediterranean Fever Pipeline Report
• DelveInsight's Familial Mediterranean Fever Pipeline analysis depicts a robust space with 3+ active players working to develop 3+ pipeline treatment therapies.
• The leading Familial Mediterranean Fever Companies are working in the market include Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others.
• Promising Familial Mediterranean Fever Pipeline Therapies in various stages of development include Canakinumab (AIN457), Canakinumab, NC-503 (Anti-amyloidotic (AA) Agent), Adalimumab, ACZ885, Apremilast, and others
• Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.
• On Feb 2023, R-Pharm International announced a long-term open-label study is an extension of the core double blind, randomized, placebo-controlled study, CL04018065. It is planned that this study will include no more than 60 patients who completed the core study, where they received blinded therapy.
Familial Mediterranean Fever Overview
Familial Mediterranean fever (FMF) is an inherited auto inflammatory disease characterized by recurrent episodes (attacks) of fever and acute inflammation of the membranes lining the abdomen, joints, and lungs. Some individuals may develop a serious condition known as amyloidosis, in which certain proteins called amyloid accumulates in various tissues of the body.
For further information, refer to the detailed Familial Mediterranean Fever Unmet Needs, Familial Mediterranean Fever Market Drivers, and Familial Mediterranean Fever Market Barriers, click here for Familial Mediterranean Fever Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Familial Mediterranean Fever Emerging Drugs Profile
• Tocilizumab: Roche
Familial Mediterranean Fever Pipeline Therapeutics Assessment
There are approx. 3+ key companies which are developing the therapies for Familial Mediterranean Fever. The companies which have their Familial Mediterranean Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Roche and others.
Request a sample and discover the recent advances in Familial Mediterranean Fever Ongoing Clinical Trial Analysis and Medications, click here @ Familial Mediterranean Fever Treatment Landscape- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Familial Mediterranean Fever Pipeline Therapeutics Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Familial Mediterranean Fever Therapeutics Market include-
Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others
Dive deep into rich insights for drugs for Familial Mediterranean Fever Pipeline, click here @ Familial Mediterranean Fever Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Familial Mediterranean Fever Pipeline Report
• Coverage- Global
• Familial Mediterranean Fever Companies- Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others.
• Familial Mediterranean Fever Pipeline Therapies- Canakinumab (AIN457), Canakinumab, NC-503 (Anti-amyloidotic (AA) Agent), Adalimumab, ACZ885, Apremilast, and others.
• Familial Mediterranean Fever Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Familial Mediterranean Fever Mergers and acquisitions, Familial Mediterranean Fever Licensing Activities @ Familial Mediterranean Fever Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Familial Mediterranean Fever Executive Summary
3. Familial Mediterranean Fever: Overview
4. Familial Mediterranean Fever Pipeline Therapeutics
5. Familial Mediterranean Fever Therapeutic Assessment
6. Familial Mediterranean Fever - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Familial Mediterranean Fever Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. Tocilizumab: Roche
13. Drug profiles in the detailed report…..
14. Pre-clinical and Discovery Stage Products
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Familial Mediterranean Fever Key Companies
18. Familial Mediterranean Fever Key Products
19. Familial Mediterranean Fever- Unmet Needs
20. Familial Mediterranean Fever- Market Drivers and Barriers
21. Familial Mediterranean Fever- Future Perspectives and Conclusion
22. Familial Mediterranean Fever Analyst Views
23. Familial Mediterranean Fever Key Companies
24. Appendix
Latest Reports launched by DelveInsight:
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/infographics/chronic-hepatitis-b-virus-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exploring the Advancements in Familial Mediterranean Fever Clinical Trials: Anticipating the Arrival of 3+ Innovative Therapies into the Landscape, Insights by DelveInsight here
News-ID: 3350064 • Views: …
More Releases from DelveInsight Business Research
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain.
Explore the…
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field.
Stay informed with the latest developments! Access…
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP…
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is…
More Releases for Familial
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2 …
RnRMarketResearch.com adds “Familial Adenomatous Polyposis - Pipeline Review, H1 2017” to its store providing an overview of the Familial Adenomatous Polyposis therapeutic pipeline with comprehensive information on the therapeutic development for Familial Adenomatous Polyposis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
